Herlev Hospital Patent applications |
Patent application number | Title | Published |
20140242101 | PD-L1 BASED IMMUNOTHERAPY - The present invention relates to the field of prophylaxis and therapy of clinical conditions including cancer, autoimmune diseases and infectious diseases. In particular there is provided vaccine compositions comprising PD-L1 or peptide fragments thereof that are capable of eliciting immune responses useful in treatment of cancer, autoimmune diseases or infectious diseases. | 08-28-2014 |
20140106985 | MICRORNA BIOMARKERS FOR PROGNOSIS OF PATIENTS WITH PANCREATIC CANCER - The present invention relates to prognostic micro RNA (miRNA) biomarkers based on a specific miRNA expression pattern, which can prove as a valuable prognostic tool to predict the survival of patients being diagnosed with pancreas cancer. | 04-17-2014 |
20130310276 | MICRORNA FOR DIAGNOSIS OF PANCREATIC CANCER - The present invention relates to methods for improving the diagnosis of pancreatic and ampullary adenocarcinomas by making use of specific mi RNA biomarkers and/or mi RNA classifiers. | 11-21-2013 |
20130296995 | Method For Treating A Tissue Region With An Electric Field - A method for treating a patient by covering a tissue region with a electric field capable of transiently or permanently permeabilizing cells in said tissue region, comprising the steps of: a. positioning the electrodes of an electrode device in a tissue region to be treated; and b. creating a specific polarity pattern by applying to a first subset of electrodes comprising at least two electrodes a first polarity while at the same time applying to a second subset of electrodes comprising at least two electrodes a second polarity. | 11-07-2013 |
20110318372 | INDOLEAMINE 2,3-DIOXYGENASE BASED IMMUNOTHERAPY - The present invention relates to the field of prophylaxis and therapy of cancer. In particular there is provided a protein Indoleamine 2,3-dioxygenase (IDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of DO or peptides derived here from or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above. The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided. | 12-29-2011 |
20110045518 | YKL-40 AS A GENERAL MARKER FOR NON-SPECIFIC DISEASE - The present invention relates to methods of diagnosing the presence of a non-specific disease or disorder in a subject, wherein a determined level of YKL-40 above a reference level indicates the presence of a non-specific disease or disorder. The subject may suffer from a variety of diseases or disorders. The reference level may be a reference level obtained from healthy individuals or it may be a previous measurement obtained from the same subject. The present invention furthermore relates to a method for classifying the severity of a non-specific disease or disorder in a subject, wherein a determined level of YKL-40 above or below one or more reference levels gives the severity of said non-specific disease or disorder. The present invention further relates to a kit and a device that may be used in the method of the present invention comprising means for measuring the level of YKL-40 in a sample; and means for comparing the measured level of YKL-40 with at least one reference level of YKL-40. | 02-24-2011 |